Acino picks up Cephalon's Mideast, Africa biz; Watson, Noven in Daytrana patent fight;

@FiercePharma: Digesting $13B Nycomed buyout, #Takeda chief says Japanese managers aren't adept at integrating acquisitions - WSJ. Report | Follow @FiercePharma

> Switzerland's Acino has agreed to buy Cephalon's ($CEPH) business in the Middle East and Africa for €80 million, including €60 million in cash. Article

> Watson Pharmaceuticals ($WPI) has asked the FDA to approve its generic version of Noven Pharmaceuticals' ADHD treatment Daytrana. Noven responded by suing for patent infringement. Story

> New York-based drug importer Medisca pleaded guilty to a misdemeanor and admitted it had claimed its unapproved, Chinese-made human growth hormone was cleared by the FDA. Report

> Some Indian patient groups and industry leaders are questioning whether the country's Competition Commission is qualified to police foreign M&A as new proposals would require. News

> Johnson & Johnson ($JNJ) plans to release its third-quarter results Tuesday morning before the market opens. Item

> Apotex got the FDA nod for Ferriprox, its treatment for the iron-related blood disorder thalassemia. Article

> Actavis donated $2.7 million worth of medicines, including heart drugs and anti-infectives, to Libya to help alleviate local shortages. Story

Biotech News 

@FierceBiotech: Twitter opinions linked to vaccine uptake. Item | Follow @FierceBiotech

@JohnCFierce: My first reaction to the Anadys deal? Looks like Roche is figuring that if it's worth anything, they got it cheap. Article | Follow @JohnCFierce

@RyanMFierce: FDA extends halt that began in August on Insmed's trial for inhaled antibiotic. $INSM stock takes hit. Story | Follow @RyanMFierce

@MaureenFierce: Tech needed to stop Twitter from becoming platform for pushers of fake, substandard drugs. Article By @Nick__Taylor. | Follow @MaureenFierce

> Working on a cure, Roche scoops up Anadys hep C drugs in $230M buyout. Article

> Sofinnova bucks a bleak trend with $440M biotech fund. Report

> Harvard project takes aim at improving drug development odds. Item 

Medical Device News

> Boston Sci launches Promus Element stent system in China. Article

> Eucomed to launch conference pre-vetting system. Story

> Analyst names medtech firms ripe for M&A. Report

Biotech IT News

> Google Earth marks sources of infection. Article

> Robot scientist passes big bio test. Story

> Bayer tackles informatics challenges in cancer research. News

> Accelrys brings drug discovery projects to the cloud. Report

> Google VC unit takes lead role DNAnexus's $15M round, hosting huge DNA database. Item

And Finally... To keep counterfeit drugs from setting up a beachhead on Twitter, new filtering technologies are needed, researchers say. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.